InflaRx cans Gohibic development after skin disease trial stopped for futility
InflaRx is to cease work on its intravenous complement inhibitor Gohibic for the skin condition pyoderma gangrenosum after an interim analysis indicated that a Phase 3 trial would fail. The study’s independent data monitoring committee ...
InflaRx is to cease work on its intravenous complement inhibitor Gohibic for the skin condition pyoderma gangrenosum after an interim analysis indicated that a Phase 3 trial would fail.
The study’s independent data monitoring committee ...
